{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T09:56:03Z","timestamp":1693130163026},"reference-count":88,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.beha.2012.10.008","type":"journal-article","created":{"date-parts":[[2012,11,9]],"date-time":"2012-11-09T05:45:58Z","timestamp":1352439958000},"page":"453-464","source":"Crossref","is-referenced-by-count":5,"title":["What is the impact, present and future, of novel targeted agents in acute lymphoblastic leukemia?"],"prefix":"10.1016","volume":"25","author":[{"given":"Dan","family":"Douer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2012.10.008_bib1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.beha.2008.08.004","article-title":"Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?","volume":"21","author":"Douer","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2012.10.008_bib3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.6004\/jnccn.2012.0089","article-title":"Acute lymphoblastic leukemia","volume":"10","author":"Alvarnas","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.beha.2012.10.008_bib4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib5","article-title":"Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05\/93","volume":"98","author":"G\u00f6kbuget","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib6","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib7","doi-asserted-by":"crossref","first-page":"521a","DOI":"10.1182\/blood.V106.11.1833.1833","article-title":"Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia (ALL): final results from cancer and leukemia Group B study 19802","volume":"106","author":"Stock","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib8","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib9","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib10","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","article-title":"Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia","volume":"20","author":"Linker","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.6516","article-title":"A randomized trial demonstrating the superiority of cytarabine with high-dose mitoxantrone compared to a standard vincristine\/prednisone-based regimen as induction therapy for adult patients with ALL","volume":"23","author":"Weiss","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib12","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2012.10.008_bib13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0025-7125(16)32504-4","article-title":"Changing concepts of treatment in acute leukemia","volume":"55","author":"Clarkson","year":"1971","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.beha.2012.10.008_bib14","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood.V64.1.38.38","article-title":"Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults","volume":"64","author":"Hoelzer","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2012.10.008_bib17","first-page":"S127","article-title":"The U.S. trials in adult acute lymphoblastic leukemia","volume":"83","author":"Larson","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2012.10.008_bib18","first-page":"1556","article-title":"A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111","volume":"92","author":"Larson","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib19","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia Group B Study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib20","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib21","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1182\/blood-2010-12-283093","article-title":"Malignant hematologic diseases in adolescents and young adults","volume":"117","author":"Wood","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib22","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2007.13.7265","article-title":"Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96","volume":"26","author":"Ribera","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib23","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.302.302","article-title":"PEG-asparaginase in adult acute lymphoblastic leukemia (ALL): efficacy and feasibility analysis with increasing dose levels","volume":"112","author":"Goekbuget","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib25","doi-asserted-by":"crossref","first-page":"181a","DOI":"10.1182\/blood.V110.11.587.587","article-title":"A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia","volume":"110","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib26","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1928.1928","article-title":"Sustained and prolonged asparagine depletion by multiple doses of intravenous pegylated asparaginase in the treatment of adults with newly diagnosed acute lymphoblastic leukemia","volume":"112","author":"Douer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib27","unstructured":"No authors listed. An intergroup phase 2 clinical trial for adolescents and young adults with untreated acute lymphoblstic leukemia (ALL). Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00558519 [Accessed 14.8.12]."},{"key":"10.1016\/j.beha.2012.10.008_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2012.10.008_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.seminoncol.2011.11.009","article-title":"Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle","volume":"39","author":"Bruggemann","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib30","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Bruggemann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib31","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib32","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1200\/JCO.2005.05.047","article-title":"Molecular genetics of acute lymphoblastic leukemia","volume":"23","author":"Armstrong","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/leu.2009.18","article-title":"Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions","volume":"23","author":"Mullighan","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2012.10.008_bib34","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2012.10.008_bib35","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, hispanic\/latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib36","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1078-0432.CCR-10-1203","article-title":"New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice","volume":"17","author":"Mullighan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2012.10.008_bib37","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO.1997.15.2.476","article-title":"Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group","volume":"15","author":"Dekker","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib38","first-page":"5601","article-title":"Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia","volume":"43","author":"Sallan","year":"1983","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2012.10.008_bib39","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2012.10.008_bib40","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib41","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib42","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib43","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib44","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1002\/cncr.25319","article-title":"Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen","volume":"116","author":"Thomas","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2012.10.008_bib45","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/pbc.22209","article-title":"A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report","volume":"53","author":"Angiolillo","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beha.2012.10.008_bib46","article-title":"Incorporation of alemtuzumab into front-line therapy of adult acute lymphoblastic leukemia (ALL) is feasible: a phase I\/II study from the cancer and leukemia Group B (CALGB 10102)","volume":"106","author":"Stock","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib47","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood-2008-06-164129","article-title":"CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy","volume":"112","author":"Dworzak","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib48","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2012.10.008_bib50","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2006-04-016709","article-title":"Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia","volume":"108","author":"Jeha","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib51","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.170.170","article-title":"Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07\/2003","volume":"116","author":"Hoelzer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib52","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib53","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood-2004-09-3785","article-title":"The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"105","author":"Lee","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib54","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib55","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib56","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib57","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib58","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.hoc.2009.07.007","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"23","author":"Ravandi","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.beha.2012.10.008_bib59","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib60","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Foa","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib61","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.247.247","article-title":"Updated long-term results of a randomized comparison of prophylactic and pre-emptive imatinib following allogeneic stem cell transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"118","author":"Pfeifer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib62","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.beha.2012.10.008_bib63","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib64","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.6500","article-title":"Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed\/refractory B-precursor ALL","volume":"30","author":"Topp","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib65","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2012-02-410373","article-title":"CARs and cancers: questions and answers","volume":"119","author":"Brentjens","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib66","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib67","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2012.10.008_bib68","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/ni1121","article-title":"CD22 regulates B lymphocyte function in\u00a0vivo through both ligand-dependent and ligand-independent mechanisms","volume":"5","author":"Poe","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.beha.2012.10.008_bib69","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib70","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.6501","article-title":"Inotuzumab ozogamycin (IO), a CD22 monoclonal antibody conjugated to calecheamicin, given weekly, for refractory-relapse acute lymphocytic leukemia (R-R ALL)","volume":"30","author":"Jabbour","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib71","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.248.248","article-title":"A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL)","volume":"118","author":"Wayne","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1703602","article-title":"Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease","volume":"30","author":"Cohen","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2012.10.008_bib73","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/1535-7163.MCT-11-0632","article-title":"Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies","volume":"11","author":"Sharkey","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.beha.2012.10.008_bib74","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/leu.2010.205","article-title":"NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951","volume":"24","author":"Clappier","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2012.10.008_bib75","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2009.22.0996","article-title":"Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII\/ECOG E2993 protocol","volume":"27","author":"Mansour","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.10.008_bib76","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience","volume":"93","author":"Wetzler","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib77","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib78","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3960\/jslrt.50.91","article-title":"11q23\/MLL acute leukemia: update of clinical aspects","volume":"50","author":"Tamai","year":"2010","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.beha.2012.10.008_bib79","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood.V90.11.4532","article-title":"Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study","volume":"90","author":"Mrozek","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib80","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2003-02-0434","article-title":"AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases","volume":"102","author":"Schoch","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib81","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib82","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib83","doi-asserted-by":"crossref","first-page":"6912","DOI":"10.1182\/blood-2011-02-334359","article-title":"DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis","volume":"117","author":"Nguyen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib84","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2012.10.008_bib85","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beha.2012.10.008_bib86","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2005-03-1309","article-title":"A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)","volume":"106","author":"Gandhi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.10.008_bib87","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/leu.2008.318","article-title":"Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia","volume":"23","author":"Deenik","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2012.10.008_bib88","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3324\/haematol.2010.026997","article-title":"The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia","volume":"96","author":"Saunders","year":"2011","journal-title":"Haematologica"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T21:47:42Z","timestamp":1594849662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692612000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1521692612000862"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2012.10.008","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}